This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Emotional and Cardiac Impact of Postpartum Haemorrhage (HELP-MOM)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT02118038
First received: March 27, 2014
Last updated: January 10, 2017
Last verified: January 2017
  Purpose
To assess the impact and to identify the main risk factors for psychological and cardiac morbidity (post-traumatic stress disorder, anxiety and depression) in case of postpartum hemorrhage

Condition
Postpartum Hemorrhage Treated With Sulprostone

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Emotional and Cardiac Impact of Postpartum Haemorrhage. Observational Study HELP-MOM.

Resource links provided by NLM:


Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Identification of risk factors for psychological impact of PPH [ Time Frame: 1 month ]
    Identification of risk factors for psychological impact of PPH, as measured three questionnaires (HELPMOM1)

  • Occurrence of a cardiac event [ Time Frame: Day0 ]
    Occurrence of a cardiac event, defined as an elevation of troponin or BNP or an EKG modification during the acute phase of postpartum hemorrhage (PPH) (HELPMOM2)

  • Identification of risk factors for psychological impact of PPH [ Time Frame: 3 months ]
    Identification of risk factors for psychological impact of PPH, as measured three questionnaires (HELPMOM1)

  • Identification of risk factors for psychological impact of PPH [ Time Frame: 6 months ]
    Identification of risk factors for psychological impact of PPH, as measured three questionnaires (HELPMOM1)


Biospecimen Retention:   Samples Without DNA
Serum and plasma

Enrollment: 329
Study Start Date: November 2014
Estimated Study Completion Date: December 2021
Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
HELPMOM1
corresponds to the cohort of patients in whom psychological state will be studied in the immediate waning PPH then during a 6 months through appropriate questionnaires
HELPMOM2
corresponds to the cohort of patients enrolled in group HELPMOM1 who experienced a cardiac abnormality in the initial management and will therefore be included in a cardiac monitoring

Detailed Description:
The HELP- MOM study is an observational study that seeks to identify the major determinants of morbidity induced by postpartum hemorrhage (PPH) in the short and medium term. Even if PPH remains the leading cause of death in the world and in France , its main impact in so-called developed countries is not so much maternal mortality ( which is very small ) but induced morbidity.Data from the literature suggest that in a number of cases, PPH is associated with cardiac abnormalities. The nature of the abnormalities, their potential impact on the functioning of the cardiovascular system of women and their evolution over time (possibility of persistent sequelae) are not known. Similarly, it is known that the postpartum period of normal pregnancy followed by a normal delivery is at risk of psychological disorders in the mother. The PPH is a very serious situation where sometimes the vital prognosis of the mother was committed. Again, determining the exact nature and consequences of psychological harm secondary PPH are not known. Finally, fertility and the risk of recurrence after an episode PPH are also poorly understood. Outside hysterectomy hemostasis which permanently affects the fertility of the patient, the severity and type of management of PPH most likely affect fertility. Only a long-term monitoring could help address this issue. Thus, HELP MOM - study aims to address these issues. To do this, HELP MOM, was divided into two sub- studies : 1) HELP-MOM 1 "multidisciplinaire" which corresponds to the cohort of patients in whom psychological state will be studied in the immediate waning PPH then during a 6 months through appropriate questionnaires , 2 ) HELP-MOM 2 "cardio" that corresponds to the cohort of patients who experienced a cardiac abnormality in the initial management and will therefore be included in a cardiac monitoring.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with postpartum hemorrhage
Criteria

Inclusion Criteria:

HELPMOM1 :

  • Patients with postpartum hemorrhage and receiving sulprostone
  • Patient affiliated with social security

HELPMOM2 :

  • Enrolled HELMOM1
  • Presence of one or more items from the following list at the moment of PPH:

    • elevated troponin ("classical" or ultra) exceeds 5 times the normal value (about> 0.20 g / ml depending on the laboratory) and / or
    • electrocardiographic abnormalities (ST-segment abnormalities and / or T wave abnormalities searched in all 12 leads) and / or
    • rate of BNP (Brain Natriuretic Peptide) greater than 100 pg / m

Exclusion Criteria:

HELPMOM1:

  • Age < 18 years
  • Hemorrhage caused by a miscarriage, a clandestine abortion, fetal death in utero or medical or voluntary termination of pregnancy.

HELPMOM2:

- Patient with pace maker

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02118038

Locations
France
Département Anesthésie et Réanimation - Hôpital Lariboisière
Paris, France, 75010
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Study Chair: Etienne GAYAT, MD, PhD Assistance Publique - Hôpitaux de Paris
Principal Investigator: Alexandre MEBAZAA, MD, PhD Assistance Publique - Hôpitaux de Paris
  More Information

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02118038     History of Changes
Other Study ID Numbers: P111013
2013-A01062-43 ( Other Identifier: IDRCB )
Study First Received: March 27, 2014
Last Updated: January 10, 2017

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Postpartum haemorrhage
Sulprostone
Cardiac impact
Emotional impact
Cardiac magnetic imaging resonance

Additional relevant MeSH terms:
Hemorrhage
Postpartum Hemorrhage
Pathologic Processes
Obstetric Labor Complications
Pregnancy Complications
Puerperal Disorders
Uterine Hemorrhage

ClinicalTrials.gov processed this record on July 17, 2017